Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

被引：0
|
作者：
Charles E. Frost
Van Ly
Samira M. Garonzik
机构：
[1] Bristol Myers Squibb,Research and Development
来源：
Drugs in R&D | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：375 / 384
页数：9
相关论文
共 50 条
  • [31] Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
    Marcinak, John
    Vakilynejad, Majid
    Kogame, Akifumi
    Tagawa, Yoshihiko
    [J]. DRUGS IN R&D, 2018, 18 (02) : 109 - 118
  • [32] Mild to moderate hepatic insufficiency does not affect pharmacokinetics and pharmacodynamics of tirofiban
    Depré, M
    Lo, MW
    Van Hecken, A
    De Lepeleire, I
    Hand, EL
    Lowry, R
    Connor, JG
    Murphy, MG
    Fevery, J
    De Schepper, PJ
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R458 - R458
  • [33] Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment
    Haijing Yang
    Min Zhang
    Yuancheng Chen
    Hong Ren
    Hong Zhang
    Chen Yu
    Jianda Lu
    Li You
    Jicheng Yu
    Hong Liang
    Cuilan Xiao
    Zishuang He
    Jufang Wu
    Jun Xue
    Jing Zhang
    [J]. European Journal of Clinical Pharmacology, 2022, 78 : 1079 - 1086
  • [34] Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment
    Yang, Haijing
    Zhang, Min
    Chen, Yuancheng
    Ren, Hong
    Zhang, Hong
    Yu, Chen
    Lu, Jianda
    You, Li
    Yu, Jicheng
    Liang, Hong
    Xiao, Cuilan
    He, Zishuang
    Wu, Jufang
    Xue, Jun
    Zhang, Jing
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (07) : 1079 - 1086
  • [35] THE EFFECT OF MILD TO MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF ALISPORIVIR (ALV)
    Kovacs, S. J.
    Ke, J.
    Praestgaard, J.
    Barve, A.
    Zhang, J.
    Maietta, R.
    Sunkara, G.
    Stein, D. S.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S345 - S345
  • [36] Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics and Safety of Carisbamate
    Moore, Kenneth
    Zannikos, Peter
    Solanki, Bhavna
    Greenspan, Andrew
    Verhaeghe, Tom
    Brashear, H. Robert
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (05): : 738 - 746
  • [37] FTY720 pharmacokinetics in mild to moderate hepatic impairment
    Kovarik, JM
    Schmouder, RL
    Wang, SY
    Wiegand, H
    Dilzer, SC
    Lasseter, KC
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (04): : 446 - 452
  • [38] PHARMACOKINETICS OF TMC435 IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT
    Sekar, V.
    Simion, A.
    Peeters, M.
    Spittaels, K.
    Lawitz, E.
    Marbury, T. C.
    De Smedt, G.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S193 - S193
  • [39] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (08): : 944 - 952
  • [40] Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment
    Venkatakrishnan, Karthik
    Liu, Yi
    Noe, Dennis
    Mertz, Jaime
    Bargfrede, Michael
    Marbury, Thomas
    Farbakhsh, Kambiz
    Oliva, Cristina
    Milton, Ashley
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (06) : 986 - 997
12345